Spruce Biosciences, a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders, including its lead program for congenital adrenal hyperplasia (CAH), announced yesterday that it has named David Moriarty, PhD as its new vice president of Development Operations.

Prior to joining Spruce, Dr Moriarty served as vice president of Clinical Operations and Data Management at Jazz Pharmaceuticals. Before Jazz, he was responsible for leading clinical operations in different Janssen Pharmaceutical Alzheimer's Disease late development clinical programs over several years. Earlier at Janssen, formerly Tibotec Therapeutics, he held clinical operations roles leading to the approved HIV therapies of Prezista and Edurant. He also held prior positions of increasing responsibility at PPD, a global CRO, working primarily on the late development work of Humira for Abbott Pharmaceuticals.

Moriarty said, 'I am pleased to join the talented team at Spruce with the objective of developing a new, effective therapy that will potentially benefit patients with CAH. I am looking forward to leveraging my experience as a clinical development leader of now-approved products through the clinical trial process on behalf of Spruce, as the company advances its lead program in CAH.'